BlogHeader.png

Alcami Introduces Seamless Customer Experience with New Customer Portal and Application, Alcami OnDemand™

  • Unprecedented access, transparency and visualization of projects
  • Easy to use platform for submitting samples for analytical testing and checking project status
  • Provides a single source for order and project management with customer access to historical submissions and reports

Wilmington, NC (USA) – March 22, 2017 – Alcami, a leading provider of custom development and manufacturing services for the pharmaceutical and biotechnology industries, is setting the industry standard for project management and transparency with its new Customer Portal and Mobile Application: Alcami OnDemand™. The initial phase will concentrate on the sample submission process within its Analytical Testing offering.

Topics: Company News

SCIENTIST SPOTLIGHT: March 2017


Name:
Elsie Melsopp
Alcami Site: Wilmington, NC

How long have you been with Alcami?
I will be celebrating my 20 year anniversary on March 17, 2017.

What is your role?
I lead the solids formulation development group, which is part of development services at our Wilmington, NC site.

What is the most rewarding part of your job?
Sharing the success of our customers and contributing to the pharmaceutical sciences.

What are your team’s latest achievements?  

Topics: Alcami Voices

Executive Q&A: Keys to Cultural Integration


As published in Pharma's Almanac Q1 2017.


Catherine Hanley, Alcami Director of Marketing, discusses with Nigel Walker of That's Nice how to successfully integrate after a merger.

Why is cultural integration following a merger so important to the success of the newly formed entity?

The impact on employee morale and turnover can be painfully high during and after a merger, and repairing it can be nearly impossible. If cultural integration doesn't happen, companies see significant and costly consequences.

 

Topics: Thought Leadership

Editorial: Supporting the Pharma Industry Small Business Growth Engine

As published in Pharma's Almanac Q1 2017.


Small and medium-sized companies generate
greater than two-thirds of the clinical candidates
in the pharma and biotech industry drug pipeline.
They often, however, lack the knowledge and
resources required to take a new medicine from
the lab to the market and need support
from CDMOs that offer integrated, tailored,
customized solutions and personalized
technical support.

Topics: Thought Leadership

Alcami Attending DCAT Week '17


Alcami will be attending DCAT Week '17, to be held March 20-23, 2017 in New York, NY.

DCAT Week is the premier business development event for companies engaged in pharmaceutical development and manufacturing and related industries. It is organized and hosted by the Drug, Chemical & Associated Technologies Association (DCAT) to assist its member companies with their business development objectives. Held annually in March, the event’s unique model brings together members for high-level strategic meetings with key decision makers, timely educational programs and important networking opportunities.

Topics: Events

Alcami in Action: 2016 in Review

Alcami is proud to have an established Foundations Team comprised of cross-functional team members from every site in our company. Committed to strengthening partnerships within our local communities, the team assesses and makes decisions about community outreach activities, charitable and nonprofit opportunities, sponsorships and memberships. The team’s overall mission is to determine how Alcami and its employees can best connect with the communities in which they live and work. Combining company resources with their own, the team supports charitable and community organizations that advance the health industry, as well as STEM, economic, environmental and other social initiatives that align with the company’s mission and values. In addition to direct financial contributions, employees seek to make a difference in each of the communities in which we do business through strong volunteer partnerships. We look forward to our continued involvement in our local communities in 2017, but first let's revisit some highlights from 2016:

Topics: Alcami in Action

Alcami Invests in Bruker’s D8 DISCOVER HTS™ System for High-Throughput X-Ray Diffraction Screening in Pharmaceutical Formulation Development

Weert, The Netherlands and Karlsruhe, Germany – March 3, 2017 – Alcami, a leading provider of custom development and manufacturing services for the pharmaceutical and biotechnology industries, and Bruker AXS, one of the world's leading suppliers of analytical X-ray solutions, today announced the delivery of Bruker’s D8 DISCOVER HTS™ high-throughput X-ray Diffraction (XRD) analysis system to the Alcami site in Weert, The Netherlands.

Topics: Company News

Executive Brief: An Opioid Abuse-Deterrent Roadmap for the Pharmaceutical Industry

Since 1999, deaths from prescription opioids—drugs like oxycodone, hydrocodone, and methadone—have quadrupled, causing more than 165,000 deaths in the U.S. 

Topics: Resource Center

Antibiotic Potency Testing: The Methods - Part 2

Using the Turbidimetric Method

In part one of this blog series, we discussed Antibiotic Potency Testing using the Diffusion (Cylinder-Plate) method.

Antibiotic potency assays using microbiological methods are required by both the European and United States Pharmacopoeia for some antibiotic products. Physicochemical methods, such as immunological assays and High-Performance Liquid Chromatography (HPLC) have become commonplace for determining the concentration of API and for the concomitant determination of Assay and impurities. However, microbiological assays provide a true measure of how effectively an antibiotic kills or inhibits a target microorganism at a specified concentration.

Topics: Thought Leadership

WHITE PAPER: Abuse-Deterrent Studies for Controlled Drugs - A Changing Landscape

Alcami has recently authored a white paper regarding the changing landscape in abuse-deterrent studies for controlled drugs. 

  • Governmental and regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and Department of Health and Human Services (HHS), have made significant investments towards the reduction of the misuse of prescription drugs.

    Engineering abuse-deterrent properties into prescription forms of drugs with abuse potential has become a primary strategy for abuse prevention.

Topics: Resource Center